Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment.
How the approach to analyse human challenge data for influenza with AI is the first of its kind.
Next steps after the successful conclusion of the collaboration, moving towards partnership
Why Poolbeg is at the forefront of AI-enabled drug discovery